INTRODUCTION {#s1}
============

*CHEK2* (checkpoint kinase 2) is a tumor-suppressor gene involved in cell cycle arrest and encodes a serine/threonine-protein kinase (CHEK2) activated in response to double-strand DNA damage ([@THIBODEAUMCS001628C69]). Multiple case--control studies have reported an association between the truncating variant *CHEK2*:c.1100delC (NM_007194.3:c.1100delC, rs555607708, hg19 Chr22:g.29091856AG\>A) in the heterozygous state and breast cancer risk in *BRCA1*/*BRCA2*-mutation-negative women ([@THIBODEAUMCS001628C41]; [@THIBODEAUMCS001628C65]; [@THIBODEAUMCS001628C14]). The consensus view is that this variant confers an approximately twofold increase in breast cancer risk above that of the general population and is a moderate penetrance allele ([@THIBODEAUMCS001628C41]; [@THIBODEAUMCS001628C65]; [@THIBODEAUMCS001628C14]). Breast cancers associated with *CHEK2*:c.1100delC are predominantly estrogen receptor (ER)-positive ([@THIBODEAUMCS001628C43]; [@THIBODEAUMCS001628C66]; [@THIBODEAUMCS001628C28], [@THIBODEAUMCS001628C29]). More recently, *CHEK2*:c.1100delC has been associated with an increased risk of other cancers (hazard ratio \[HR\] 1.45, 95% confidence interval \[CI\] 1.15--1.82), among which stomach (HR 5.76, 95% CI 2.12--15.6) and kidney (HR 3.61, 95% CI 1.33--9.79) cancers, as well as sarcomas (HR 3.45, 95% CI 1.09--10.9), displayed the highest increase in risk ([@THIBODEAUMCS001628C44]). Furthermore, this variant, in its homozygous state, has also been reported in some families with Li--Fraumeni syndrome type 2 (MIM \#609265) ([@THIBODEAUMCS001628C7]; [@THIBODEAUMCS001628C63]). No association has been observed with uterine or genital type leiomyosarcoma (LMS), presumably because of the rarity of this tumor type. The incidence rate of LMS in the United States is 12.3 per million ([@THIBODEAUMCS001628C61]), but it is reported as low as 4 per million in European Nordic countries ([@THIBODEAUMCS001628C27]). As per the Exome Aggregation Consortium (ExAC) database, the highest minor allele frequency of *CHEK2*:c.1100delC (NM_007194.3, rs555607708) is in the Finnish population at ∼0.008, followed by non-Finn Europeans at 0.002 ([@THIBODEAUMCS001628C33]).

An optimal treatment regime specifically for breast cancer patients carrying the *CHEK2*:c.1100delC mutation has yet to be elucidated, and it is still unknown why these patients have poorer prognosis when compared with noncarriers or why they are at increased risk of a second metachronous breast cancer ([@THIBODEAUMCS001628C66]; [@THIBODEAUMCS001628C28]; [@THIBODEAUMCS001628C48]). A recent study showed that breast cancer risk was similar in *CHEK2* founder versus nonfounder mutation carriers and that the risk of multiple primary cancers of different origin was also increased ([@THIBODEAUMCS001628C31]).

We identified the *CHEK2*:c.1100delC variant in the LMS tumor sample as well as the blood from a patient with concomitant diagnoses of both pelvic genital type LMS and metastatic invasive ductal breast carcinoma.

RESULTS {#s2}
=======

Clinical Presentation and Family History {#s2a}
----------------------------------------

### Patient---Oncological History {#s2a1}

We describe a 61-yr-old female with synchronous diagnoses of pelvic genital type LMS and metastatic breast cancer.

At 59 yr of age, the patient had abdominal computed tomography (CT) imaging in the context of abdominal pain, which revealed a left nephrolithiasis, multiple uterine fibroids, and what initially appeared to be a right adnexal solid mass (6.7 × 7 cm) possibly associated with the uterus. The patient underwent subtotal hysterectomy and bilateral salpingectomy--oophorectomy, but the additional separate pelvic mass (10--12 cm) was firmly adherent to the right posterolateral pelvic wall and could not be excised. Histopathological examination of the uterus showed multiple benign cellular leiomyomata. A repeat pelvic MRI showed a 15-cm centrally necrotic pelvic mass with cystic component and local invasion along the pelvic wall and right sacroiliac joint with mass effect leading to compression of the bladder. Within a 4-mo period, the mass had doubled in size from 7 to 15 cm. A CT-guided transgluteal biopsy of the pelvic mass was obtained and revealed features in keeping with pelvic genital type LMS ([Fig. 1](#THIBODEAUMCS001628F1){ref-type="fig"}). The patient underwent local radiation therapy, subsequent repeat attempted resection (unsuccessful), and then received single-agent adriamycin (six cycles). A CT-guided biopsy of the mass was then obtained at the time of therapeutic pelvic cyst drainage and was used for both genomic and transcriptome profiling ([@THIBODEAUMCS001628C30]).

Concurrently, breast imaging (mammography and ultrasound) was performed in the context of a right-sided breast lump and revealed a 7.5 × 4 × 3 cm mass with several abnormal lymph nodes in the right axilla. Fine needle aspiration biopsy showed epithelioid cells suggestive of malignancy and core needle biopsies revealed ER-positive, PR-positive, HER2-positive invasive ductal carcinoma (Nottingham grade 2) ([Fig. 2](#THIBODEAUMCS001628F2){ref-type="fig"}). The patient underwent right mastectomy and axillary lymph node dissection.

![Leiomyosarcoma of genital type. (*A*) Photomicrograph showing a highly cellular smooth muscle neoplasm with elongated blunt-ended nuclei and abundant eosinophilic cytoplasm characteristic of muscle lineage with hematoxylin and eosin (H&E) stain (larger image 20× magnification; *inset*, 200× magnification). (*B*) Immunostains showing strong and diffuse positive staining for muscle-specific actin (*upper left*), desmin (*upper right*), heavy chain myosin (*lower left*), and H-caldesmon (*lower right*) (100× magnification). (*C*) The immunostain for Ki-67 showed a proliferative index of ∼20% in some parts of the tumor (200× magnification). (*D*) The tumor was diffusely positive for estrogen receptors (200× magnification).](ThibodeauMCS001628_F1){#THIBODEAUMCS001628F1}

![Invasive ductal breast carcinoma with infiltrating margins. (*A*) Low-power photomicrograph showing invasive ductal carcinoma (H&E, 40× magnification). (*B*) Invasive ductal carcinoma surrounding a normal breast duct (H&E, 100× magnification). (*C*) Invasive ductal carcinoma displaying grade 2 nuclei (H&E, 200× magnification).](ThibodeauMCS001628_F2){#THIBODEAUMCS001628F2}

Initial systemic treatment consisted of letrozole and trastuzumab therapy, whereas radiation and attempted resection was directed toward the unresectable pelvic mass. The patient underwent local radiation therapy with subsequent repeat attempted resection (unsuccessful), and then received single-agent adriamycin (six cycles). Trastuzumab was discontinued after five doses to avoid cardiotoxicity when palliative treatment began with adriamycin/doxorubicin (six cycles) for the unresectable symptomatic LMS.

The patient currently remains on letrozole for treatment of both the pelvic genital type LMS and the postsurgical management of her breast cancer (high risk recurrence). Clinical and radiological assessment is suggestive of pelvic disease stabilization, but subtle signs of slow progression are noted (e.g., adenopathy).

### Patient---Other Medical Conditions {#s2a2}

This patient was diagnosed with rheumatoid arthritis in her early 40s. She was treated with rituximab for 8 yr, which was discontinued following her breast cancer and pelvic genital type LMS cancer diagnoses. Other comorbidities included insulin resistance, hypothyroidism, hypertension, nephrolithiasis, osteoporosis, and polycystic ovarian syndrome (PCOS).

### Family History {#s2a3}

The patient is of Irish (maternal) and mixed Native American/German (paternal) ancestry. She has three healthy daughters. The patient is from a sibship of four. Detailed family history revealed two cases of premenopausal breast cancer in second-degree relatives: a niece, diagnosed with ER-positive breast cancer at age 35 (treated with lumpectomy and radiation therapy) and a paternal aunt, diagnosed with breast cancer in her 30s.

Pathology {#s2b}
---------

### LMS {#s2b1}

The sections showed a highly cellular smooth muscle neoplasm ([Fig. 1](#THIBODEAUMCS001628F1){ref-type="fig"}A). At the periphery of the lesion, the neoplastic cells were better differentiated and were clearly of smooth muscle lineage having elongated blunt-ended nuclei and abundant eosinophilic cytoplasm. Here, mitotic figures were scanty. Toward the more central region of the tumor the cells were small, had crowded nuclei, and scanty cytoplasm. Zonal necrosis was seen. Mitotic figures numbered up to 10 in 10 high-power fields. Immunostains showed the tumor to be strongly and diffusely positive for muscle-specific actin, desmin, heavy chain myosin, and H-caldesmon ([Fig. 1](#THIBODEAUMCS001628F1){ref-type="fig"}B). The immunostain for Ki-67 showed a proliferative index of ∼20% in the cellular areas of the tumor ([Fig. 1](#THIBODEAUMCS001628F1){ref-type="fig"}C). The tumor was diffusely positive for ERs ([Fig. 1](#THIBODEAUMCS001628F1){ref-type="fig"}D). The stain for p16 was positive in \<10% of tumor nuclei.

Based on the age of the patient, the lack of history of progestogen therapy, the documented increase in size of the mass over the period of a few months, the presence of mitoses, and the presence of necrosis, the tumor was regarded as an LMS of genital type, French grade 2 using the grading system for peripheral soft tissue sarcoma.

### Invasive Ductal Carcinoma {#s2b2}

The breast carcinoma was 6 cm in greatest dimension. Sections showed invasive ductal breast carcinoma (Nottingham grade 2, ER/progesterone receptor (PR)-positive, HER2-positive) with infiltrating margins ([Fig. 2](#THIBODEAUMCS001628F2){ref-type="fig"}A,B) and grade 2 nuclei ([Fig. 2](#THIBODEAUMCS001628F2){ref-type="fig"}C). Lymphovascular invasion and metastases to all 18 axillary and intramammary lymph nodes with extensive extranodal extension was evident (pT3, N3a, M0).

Genomic Results {#s2c}
---------------

### Germline {#s2c1}

Whole-genome sequencing of a fresh-frozen core biopsy sampling of the LMS (in comparison with whole-genome sequencing of matched peripheral blood) revealed the heterozygous germline *CHEK2*:c.1100delC truncating variant, present in the germline and retained in the tumor. This was subsequently confirmed clinically via Sanger sequencing of peripheral blood. There was no evidence of a second somatic aberration to the wild-type *CHEK2* allele such as loss of heterozygosity (LOH) or a second somatic *CHEK2* pathogenic variant. This is in keeping with previous scientific evidence reported in the breast cancer literature ([@THIBODEAUMCS001628C56]). Furthermore, *CHEK2* gene expression was found to be low compared with other sarcomas (SARC) but comparable to normal tissue expression ([Table 1](#THIBODEAUMCS001628TB1){ref-type="table"}).

###### 

Copy number RNA expression metrics of selected genes in our leiomyosarcoma (LMS) tumor compared with the gene expression distribution from RNA-seq pooled data of all TCGA tumors, all TCGA matched normal, TCGA sarcoma tumors, and Illumina Human Body Map 2.0 (data from 16 human tissue types)

  Gene        Copy number (diploid model)   All TCGA   All TCGA (matched normal)   SARC TCGA   Bodymap                  
  ----------- ----------------------------- ---------- --------------------------- ----------- --------- ----- -------- -------
  *AKT1*      2                             2          −1.37                       0           −1.70     0     −1.49    −1.01
  *AP4B1*     1                             25         −0.32                       50          −0.16     4     −0.46    +1.04
  *AR*        3                             75         +0.89                       54          +0.10     79    +1.24    −2.7
  *ATM*       2                             48         −0.03                       43          −0.13     58    +0.17    −1.58
  *ATRX*      3                             72         +0.47                       60          +0.17     84    +0.89    −1.64
  *BRCA1*     2                             35         −0.25                       77          +0.71     23    −0.44    −1.21
  *CD27*      2                             46         −0.06                       52          0.04      62    0.24     −1.36
  *CD274*     2                             64         +1.03                       64          +3.04     76    +0.29    +0.28
  *CHEK2*     2                             10         −0.58                       29          −0.35     1     −0.9     −1
  *ESR1*      2                             88         +7.84                       85          +3.51     92    +11.86   +6.11
  *ERBB2*     2                             12         −0.58                       4           −0.91     20    −0.62    +1.13
  *FH*        1                             2          −0.9                        0           −0.58     7     −0.71    −2.47
  *HMGA2*     2                             95         +7.71                       100         +213.35   93    +6.79    +7.47
  *IGF2*      2                             90         +6.63                       89          +2.91     69    +0.32    +2.49
  *IGF2BP2*   2                             62         +0.31                       94          +2.21     72    +0.74    +2.38
  *JAK1*      2                             98         +3.11                       99          +2.42     100   +3.85    −1.12
  *KIT*       2                             79         +1.07                       37          −0.29     81    +1.30    −1.37
  *MED12*     3                             80         +0.73                       92          +1.19     92    1.21     +1.67
  *MDM2*      2                             71         +0.45                       90          +1.19     74    +0.64    +1.15
  *MDM4*      3                             85         +1.08                       97          +1.89     96    +1.89    −1.47
  *NFE2L2*    2                             70         +0.42                       40          −0.17     81    +0.73    +1.12
  *PLAG1*     2                             94         +2.93                       100         +5.6      94    +7.94    +2.48
  *PGR*       2                             93         +10.18                      84          +2.28     95    +3.93    +1.85
  *RAD51B*    0                             15         −0.59                       15          −0.61     14    −0.58    −1.13
  *TP53*      2                             31         −0.29                       60          +0.14     55    +0.09    +1.06

All TCGA, All TCGA (The Cancer Genome Atlas) cancers data set; SARC, sarcoma data set from TCGA; Body Map 2.0, Illumina Human Body Map 2.0; %ile, percentile; kIQR, number of interquartile range intervals away from the median; FC, fold change in gene expression.

### Somatic {#s2c2}

Briefly, whole-genome sequencing of both LMS and peripheral blood were performed to allow for comparative analysis and detection of somatic single-nucleotide variants (SNVs), indels, structural variants (SVs), and copy-number variants (CNVs). Whole-transcriptome sequencing of the LMS was also performed. The normal transcript comparator used was the compendium average from the Illumina Body Map data set and the disease expression comparator used was predominately the sarcoma (SARC) TCGA data set and to a lesser extent, the average across all TCGA tumor samples. The estimated tumor content was 42%. Please refer to Methods for more details.

The overall mutational burden was unremarkable when compared with the entire TCGA data set with 27 nonsynonymous coding SNVs (30th percentile) and four small indel events (60th percentile). There were 51 structural variants, falling at the 51st percentile among our local database of 339 diverse cancer cases ([@THIBODEAUMCS001628C30]). Please refer to [Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001628/-/DC1) for a complete list of somatic SNVs, indels, CNVs, and SVs and to [Supplemental Figures S1 and S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001628/-/DC1) for the Circos and CNV plots.

Of note, a somatic *BRCA1* variant of uncertain significance was also identified (p.Gln1327His) and *BRCA1* expression appeared comparable to other tumors ([Table 1](#THIBODEAUMCS001628TB1){ref-type="table"}). The hormone receptor gene expression profile was not an outlier with respect to percentile or fold change ([Table 1](#THIBODEAUMCS001628TB1){ref-type="table"}).

Multiple disruptive structural rearrangements were seen in *RAD51B*. The first structural variant is a deletion, hg19 Chr14:g.68219215_68986637del (767,422 bp) ([Fig. 3](#THIBODEAUMCS001628F3){ref-type="fig"}A,B), which only leaves the last exon of *RAD51B*. The second structural variant is a translocation t(12;14)(q14.3;q24.1)(g.65999147;g.68758275) event disrupting *RAD51B* in intron 7 (NM_133510.3, ENST00000471583) on Chromosome 14 ([Fig. 3](#THIBODEAUMCS001628F3){ref-type="fig"}C,D). Neither structural variant appears subclonal given the amount of supporting reads observed ([Fig. 3](#THIBODEAUMCS001628F3){ref-type="fig"}; [Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001628/-/DC1)). We can deduce that these structural variants occur on both alleles because they overlap. Therefore, given that the region containing *RAD51B* falls in is copy neutral (two copies), all copies of *RAD51B* have been disrupted and a functional protein product is unlikely ([Fig. 3](#THIBODEAUMCS001628F3){ref-type="fig"}). Expression of *RAD51B* was low by percentile ([Table 1](#THIBODEAUMCS001628TB1){ref-type="table"}), but not an extreme outlier according to the TCGA tumor distribution and normal tissue comparison ([Table 1](#THIBODEAUMCS001628TB1){ref-type="table"}). Given the estimated tumor content (42%), these expression values are probably artificially inflated by contribution of the normal tissue. The translocation breakpoint on Chromosome 12 lands 219 kb upstream of *HMGA2* (12q14.3), and *HMGA2* expression was very elevated when compared with all TCGA cancers and TCGA sarcomas ([Table 1](#THIBODEAUMCS001628TB1){ref-type="table"}).

![Structural variants disrupting both alleles of the *RAD51B* gene. (*A*) Copy-number data supporting the Chr14:g.68219215_68986637del (767,422-bp) deletion. The event was called using DELLY, demonstrating the presence of flanking reads pairs (12 paired-end reads) and spanning reads (14 split reads) supporting the deletion breakpoints. Copy number alteration (cna) ratio is plotted on the *y*-axis and genomic position is plotted on the *x*-axis. The horizontal lines represent the expected value for different copy states using the 42% diploid model (0 is copy neutral, −1 represents a heterozygous copy loss, and HOMD refers to homozygous deletion copy loss). Data points are colored blue if they fall within *RAD51B*. (*B*) A gene-level overview of the same deletion. (*C*) A chromosome-level overview of the translocation t(12;14)(g.65999147;g.68758275). The event was called using Trans-ABySS, demonstrating the presence of flanking read pairs (22 paired-end reads) and spanning reads (24 split reads) supporting the translocation breakpoint. (*D*) A gene-level overview of the same translocation breakpoint within *RAD51B*. (*E*) A transcript-level overview of all *RAD51B* breakpoints from both the translocation and deletion events. The *top* track shows the collapsed exons from all transcripts (ENSG00000182185). Translation start and end are displayed by the black discontinuous rectangle directly below the exons of the selected transcript (ENST00000471583). Domains are given by the bottom tracks and are labeled by Pfam identifiers: RecA (PF00154); DnaB-like helicase carboxy-terminal domain (PF03796); KaiC (PF06745); Rad51 (PF08423).](ThibodeauMCS001628_F3){#THIBODEAUMCS001628F3}

Increased expression of *PLAG1* and *IGF2* was also noted ([Table 1](#THIBODEAUMCS001628TB1){ref-type="table"}). There was a copy loss of *FH*, and *FH* appeared down-regulated in our patient\'s LMS (second percentile for all TCGA cancers). Interestingly enough, *FH* mutations lead to a hereditary cancer predisposition: hereditary leiomyomatosis renal cell carcinoma syndrome. Therefore, we pursued further investigation regarding *FH* status given the potential clinical implications and possibility to tailor oncological management. However, FH immunochemistry revealed positive staining in keeping with the protein being present (data not shown).

A duplication involving the majority of the Chromosome X long arm leads to *ATRX* (Xq21.1) and *MED12* (Xq13.1) copy gains. *ATRX* and *MED12* loss-of-function variants have been implicated in leiomyoma and LMS pathophysiology (Discussion and [Supplemental Discussion](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001628/-/DC1)), but no such variants were seen in our sample.

Mutational Signature Analysis {#s2d}
-----------------------------

Cancers have specific recurrent mutational signatures (patterns) associated with their underlying somatic molecular pathogenesis and these signatures guide the interpretation of genomic events leading to tumorigenesis ([@THIBODEAUMCS001628C1]). The mutational signature correlating with *BRCA1/BRCA2* loss (signature 3) (<http://cancer.sanger.ac.uk/cosmic/signatures>) accounted for \<20% (13.4%, 95% CI 6.2%--19.1%) of mutational burden ([Supplemental Table S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001628/-/DC1); [Supplemental Figs. S3, S4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001628/-/DC1)). This fell in the 50th percentile among 36 sarcomas, 69th percentile among 16 ovarian cancers, and 69th percentile among 87 breast cancers ([Fig. 4](#THIBODEAUMCS001628F4){ref-type="fig"}). However, the calculated homologous recombination deficiency score was 0, because of a lack of large-scale LOH, TAI (telomeric allelic imbalance), and LST (large-scale state transition) events. Please refer to Methods and [Supplemental Methods](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001628/-/DC1) for more details.

![Homologous recombination deficiency (HRD) score and signature 3 exposure levels (indicators of HRD status). The HRD score of the case study was 0 (circled black point), indicating that there was no large loss of heterozygosity, telomeric allelic imbalance, or large-scale transition events. Signature 3, associated with HRD, accounted for 13.4% of total somatic single-nucleotide variant burden. Shown here is a comparison of these two indicators of HRD status against 139 other cancers (36 sarcomas, 87 breast cancers, and 16 ovarian cancers).](ThibodeauMCS001628_F4){#THIBODEAUMCS001628F4}

DISCUSSION {#s3}
==========

In summary, we describe the findings of genomic profiling in an LMS patient with a germline *CHEK2*:c.1100delC variant and concomitant diagnosis of metastatic invasive ductal breast carcinoma. Of the known recurrent mutations and large rearrangements observed in leiomyomas and LMSs ([Supplemental Discussion](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001628/-/DC1)), the analysis of our patient\'s tumor revealed a translocation t(12;14) with one breakpoint disrupting *RAD51B* and the other breakpoint upstream of *HMGA2* ([@THIBODEAUMCS001628C39]; [@THIBODEAUMCS001628C8]), a large 16q deletion encompassing *FANCA* (reported in two cases) (Beck et al. 2009) and nonspecific copy gains and losses on Chromosome 1 (e.g., telomeric loss of 1p) ([@THIBODEAUMCS001628C46]; [@THIBODEAUMCS001628C62]).

The molecular mechanisms underlying the impact of germline *CHEK2* pathogenic variants in relation to tumorigenesis have not been elucidated. Somatic *CHEK2* point mutations have been identified in osteosarcomas and also rarely in lung and ovarian tumors, but not in other types of sarcomas tested in one study ([@THIBODEAUMCS001628C42]). Despite the involvement of CHEK2 protein in double-strand DNA break (DSB) repair, unlike BRCA1/BRCA2-driven tumors, somatic inactivation of the wild-type allele is uncommon in breast tumors of *CHEK2* mutation carriers ([@THIBODEAUMCS001628C56]). CHEK2 is part of a complex network of activating cascades, which is mainly regulated through phosphorylation events. The initial cellular event triggering CHEK2 activation is its phosphorylation by ataxia telangiectasia mutated (ATM) in the context of DNA damage ([@THIBODEAUMCS001628C69]). Activated CHEK2 then phosphorylates BRCA1 and BRCA2, which in return promotes homology-directed repair, a more accurate DSB repair mechanism when compared with nonhomologous end joining ([@THIBODEAUMCS001628C69]). In vivo studies have showed that *CHEK2*:c.1100delC impairs CHEK2 kinase activity and affects its oligomerization and autophosphorylation ([@THIBODEAUMCS001628C67]). Therefore, CHEK2-mediated BRCA1/BRCA2 ([@THIBODEAUMCS001628C69]) and TP53 ([@THIBODEAUMCS001628C21]) phosphorylation may be impaired. Also, this mutation may affect CHEK2 phosphorylation by ATM, a gene frequently deleted in LMS tumors ([@THIBODEAUMCS001628C62]). In our patient\'s tumor, the homologous recombination deficiency score was 0 and BRCA1/BRCA2 mutational signature (signature 3) was modest compared with tumors with a characterized loss of BRCA1/BRCA2 functionality ([@THIBODEAUMCS001628C1]). Overall, there was no evidence of double-strand DNA repair deficiency in the LMS.

Genomic Analysis---Discussion {#s3a}
-----------------------------

RAD51 recombinase has a central role in homologous recombination and double-strand DNA (dsDNA) break repair ([@THIBODEAUMCS001628C57]). RAD51B protein is part of the BCDX2 complex (RAD51B, RAD51D, XRCC2), which recruits RAD51 protein to damage foci ([@THIBODEAUMCS001628C57]). Mild *RAD51B* haploinsufficiency was shown to cause a minor increase of sensitivity to DNA-damaging agents in human colon cancer cell lines, whereas more severe *RAD51B* impairment has been associated with centrosome fragmentation and aneuploidy ([@THIBODEAUMCS001628C13]). Recurrent translocations involving both *RAD51B* (14q24.1) and *HMGA2* (12q14.3) loci play an important role in the pathogenesis of uterine leiomyoma via impaired cell-cycle checkpoint control and deficient dsDNA repair mechanisms ([@THIBODEAUMCS001628C39]). Chromosome 12 breakpoints in such rearrangements have been shown as intragenic or extragenic, the latter being observed in the current case with a breakpoint 219 kb upstream of *HMGA2* ([@THIBODEAUMCS001628C49]; [@THIBODEAUMCS001628C38]). *HMGA2* rearrangements make up a unique subtype of leiomyomas, which also feature overexpression of specific genes: *IGF2BP2*, *PLAG1*, *IGF2*, *HMGA2* ([@THIBODEAUMCS001628C40]). This is consistent with the pattern of expression observed in our LMS, with the exception of *IGF2BP2*, which displayed average expression ([Table 1](#THIBODEAUMCS001628TB1){ref-type="table"}).

Uterine leiomyomas are benign smooth muscle tumors and their potential to progress to LMS is still an area of debate in the literature ([@THIBODEAUMCS001628C16]). The acquisition of a *TP53* mutation appears to be a frequent and critical difference between leiomyoma and LMS ([@THIBODEAUMCS001628C15]). Somatic *MED12* alterations are involved in the pathophysiology of both leiomyomas (66%) and LMSs (20%) ([@THIBODEAUMCS001628C47]). Somatic *ATRX* mutations are thought to participate in LMS oncogenesis via impaired telomere-maintenance mechanisms ([@THIBODEAUMCS001628C68]). [@THIBODEAUMCS001628C37] performed whole-exome sequencing in 19 LMSs and found several somatic *TP53*, *MED12*, and *ATRX* mutations, therefore reiterating the central role of these genes in a subset of LMSs ([@THIBODEAUMCS001628C37]). These genes did not harbor somatic loss-of-function mutations nor aberrant expression in our patient\'s LMS ([Table 1](#THIBODEAUMCS001628TB1){ref-type="table"}).

Even though *FH* expression appeared low in conjunction with a somatic *FH* copy loss, FH immunochemistry revealed positive staining in keeping with the presence of the protein. This result does not support a central role for FH deficiency in the genesis of our patient\'s LMS, which is essentially in keeping with the leiomyoma subtype with *HMGA2* aberrations ([@THIBODEAUMCS001628C40]). Somatic *FH* deletion is not an uncommon event in leiomyomas and LMSs, but the exact role of this genomic alteration in smooth muscle tumor malignant progression requires further study ([@THIBODEAUMCS001628C36]).

Therapeutic Implications---CHEK2 {#s3b}
--------------------------------

BRCA1/BRCA2-driven breast cancers show enhanced response to DNA-damaging therapies such as platinum agents and poly ADP ribose polymerase (PARP) inhibitors, but reduced response to anthracycline--taxane chemotherapy regimens ([@THIBODEAUMCS001628C55]). Even though *CHEK2* mutation carriers display a particularly poor response to neoadjuvant therapy with anthracycline alone (without taxane) ([@THIBODEAUMCS001628C48]), there has been no study focusing on platinum or PARP inhibitor response within the *CHEK2* mutation carrier breast cancer group.

Functional studies of high-grade serous ovarian cancer show that low *CHEK2* expression surprisingly correlates with poorer platinum response and CHEK2 depletion leads to platinum resistance by suppressing cisplatin-induced S-phase cell cycle arrest ([@THIBODEAUMCS001628C3]). This would suggest that *CHEK2* haploinsufficiency could be a contraindication to platinum-based therapy in these patients.

Unlike BRCA1/BRCA2-driven breast cancer cases, *CHEK2* mutation carriers more frequently present with HR-positive tumors ([@THIBODEAUMCS001628C5]; [@THIBODEAUMCS001628C66]). However, how to incorporate this clinicopathological tumor feature into the context of *CHEK2* mutation carrier hormonal therapy still remains uncertain. To date, small case--control studies report no significant difference between the response of *CHEK2* mutation carriers to hormonal therapy when compared with noncarriers ([@THIBODEAUMCS001628C28], [@THIBODEAUMCS001628C29]).

[@THIBODEAUMCS001628C11] found a significantly higher incidence of inherited cancer gene mutations in their breast cancer cohort developing treatment-related leukemia, and even though only one case of *CHEK2* mutation was identified, this new association carries therapeutic implications for both cancer treatment and monitoring of secondary complications ([@THIBODEAUMCS001628C11]). Posttreatment, our patient did not present hematopoietic abnormalities suggestive of hematological malignancy.

Therapeutic Implications---Germline and Somatic Genomic Profiling {#s3c}
-----------------------------------------------------------------

Theoretically, some aspects of the genomic profiling results in this patient could suggest a platinum agent response and PARP inhibitor response: *RAD51B* alterations, very high *HMGA2* expression, and germline *CHEK2* pathogenic mutation. A recent review of literature by [@THIBODEAUMCS001628C64] on preclinical RAD51 targeting agents supports the therapeutic role of RAD51 inhibitors (likely combined with PARP inhibitors) to impair homologous recombination DNA repair and therefore induce cancer radiation and chemotherapy sensitization ([@THIBODEAUMCS001628C64]). We would therefore hypothesize that biallelic *RAD51B* disruption, such as present in our patient, may be a good prognostic factor. However, we did not identify a strongly damaging mutation or expression outlier in the DSB repair pathway. Moreover, despite the presence of several mutations in the DSB repair pathway genes and previous exposure to radiation therapy, a well-known dsDNA break inducer ([@THIBODEAUMCS001628C59]), the mutational burden was unremarkable and mutational signature 3, associated with HRD and *BRCA1/BRCA2* loss, accounted for \<20% (13.4%, 95% CI 6.2%--19.1%) of total somatic single-nucleotide variant burden. Consequently, although some aspects of our data suggest that multiple hits may potentiate DSB repair deficiency in the presence of DNA-damaging therapies and favor synthetic lethality, the current literature does not support this approach because of the lack of evidence-based studies on small effect hits in the DSB repair pathway and their clinical implications. Given the current conflicting literature on this topic, paucity of published therapeutic trials, and possible risk of harm, DNA-damaging therapy can only be considered in the setting of a clinical trial.

The hormonal status of uterine LMSs varies widely among different literature sources: ER immunohistochemistry (IHC)-positive in 18%--87% of cases ([@THIBODEAUMCS001628C4]) and androgen receptor (AR)-positive in 40%--100% of cases ([@THIBODEAUMCS001628C32]; [@THIBODEAUMCS001628C26]). Some data suggest that ER-positive LMS status is associated with a better prognosis ([@THIBODEAUMCS001628C22]; [@THIBODEAUMCS001628C26]). Clinical response to aromatase inhibitor therapy in advanced LMS is rare and has been observed solely in ER-positive tumors, with which our patient presents ([@THIBODEAUMCS001628C20]; [@THIBODEAUMCS001628C22]; [@THIBODEAUMCS001628C45]). Of note, our patient has a diagnosis of PCOS and several studies have reported increased risks of breast, endometrial, and ovarian cancer in PCOS patients ([@THIBODEAUMCS001628C10]; [@THIBODEAUMCS001628C12]). A recent meta-analysis found a significant increased risk only for endometrial cancer (odds ratio \[OR\] 2.79, CI 1.31--5.95) overall, but subgroup analysis excluding women over age 54 revealed that risk of both endometrial (OR 4.05, CI 2.42--676) and ovarian (OR 2.52, CI 1.08--5.89) cancer was increased ([@THIBODEAUMCS001628C6]).

Conclusion {#s3d}
----------

This is the first report of LMS genomic profiling in a patient with a germline *CHEK2*:c.1100delC variant and concomitant diagnosis of metastatic invasive ductal breast carcinoma. Our findings suggest that pathogenic germline *CHEK2* mutations may increase the risk of several types of malignancies, but that complete tumor genome and transcriptome analysis does not necessarily demonstrate obvious impairment of DSB repair mechanisms. We report a new possible mechanistic relationship between leiomyoma and LMS based on genomic and transcriptome data. Our results suggest that translocations with one breakpoint disrupting *RAD51B* and the second breakpoint upstream of *HMGA2* represent a genomic subtype of genital type LMS sharing similarities with leiomyoma. Both *RAD51B* alleles were disrupted, as one is involved in the translocation and the second is almost completely removed through a 767,422-bp deletion. Given the disparity between uterine leiomyoma prevalence and LMS incidence, malignant progression is thought to be rare. Our data support a role for *RAD51B* structural events associated with *HMGA2* overexpression in oncogenesis and potentially promoting the transition from leiomyoma to LMS. Future detailed genomic profiling studies are required to inform tailored treatment of such tumors and the optimal management of cancer in patients with a germline *CHEK2* mutation remains to be elucidated. Functional assessment of protein expression, such as detailed pathology review, immunochemistry testing, and proteomics, complement whole-genome and transcriptome profiling and will contribute to enhance our understanding of cancer pathogenesis.

METHODS {#s4}
=======

Sample Collection, RNA and DNA Extraction, and Library Preparation {#s4a}
------------------------------------------------------------------

Following informed consent, the patient underwent imaging-guided biopsies as part of the Personalized OncoGenomics program of British Columbia. An incisional biopsy of a 15-cm-diameter tumor from the pelvic genital type LMS was obtained. Up to eight core biopsies were collected on two separate occasions using 18-22G biopsy needles. Peripheral venous blood samples were obtained at the time of biopsy and leukocytes isolated for germline DNA analysis. DNA and RNA extraction, library construction, and sequencing were performed according to standard protocols ([@THIBODEAUMCS001628C23]). Please refer to [Supplemental Methods](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001628/-/DC1) for more details.

Sequencing and Bioinformatics {#s4b}
-----------------------------

Paired-end reads (125 bp for genome sequencing, 75 bp for transcriptome sequencing) were generated on an Illumina HiSeq2500 sequencer (Illumina Inc.; <http://www.illumina.com/>). Tumor biopsy and peripheral blood samples were sequenced to a depth of 93× and 46×, respectively, using established polymerase chain reaction (PCR)-free whole-genome sequencing and strand-specific RNA-seq protocols previously described ([@THIBODEAUMCS001628C25]). More than 267 million passed filter reads were obtained from the RNA-seq experiment. Reads were aligned to the hg19 (GRCh37) reference using BWA-align v0.5.7 ([@THIBODEAUMCS001628C34]). For both germline and somatic genomic events, variant calling and filtering was performed with mpileup and varFilter from SAMtools (v0.1.17), respectively ([@THIBODEAUMCS001628C35]; [@THIBODEAUMCS001628C53]). The *CHEK2*:c.1100delC variant was reviewed and validated by Sanger sequencing in the British Columbia Cancer Agency clinical cytogenetics laboratory.

Tumor content and ploidy model were estimated from sequencing data through analysis of the CNA (copy-number alterations) ratios and allelic frequencies of each chromosome ([@THIBODEAUMCS001628C24]; [@THIBODEAUMCS001628C19]). The tumor and matched normal samples were analyzed in conjunction to identify LOH and CNVs with CNAseq (v0.0.6) ([@THIBODEAUMCS001628C24]) and APOLLOH (v0.1.1) ([@THIBODEAUMCS001628C19]), respectively. The collection of distinct CNA and loss of LOH regions was compared with a set of theoretical models for ploidy (ranging from diploid to pentaploid) and tumor content (10% intervals from the initial estimated tumor content: 12%, 22%, 32%, 42%, 52%, 62%, 72%, 82%, 92%). The best fit for the LMS was a diploid model at 42% tumor content, which is a lower tumor content than estimated via pathology review and assessment (72.5%).

A combination of tools was used to perform somatic SNV calling: SAMtools (v0.1.17) ([@THIBODEAUMCS001628C35]), MutationSeq (v1.0.2) ([@THIBODEAUMCS001628C17]), and Strelka (v1.0.6) ([@THIBODEAUMCS001628C52]); small insertions and deletions were identified using Strelka (v1.0.6) ([@THIBODEAUMCS001628C52]) and Trans-ABySS (v1.4.10) ([@THIBODEAUMCS001628C9]; [@THIBODEAUMCS001628C54]). Small-mutation (SNV, indel) calling takes into consideration the tumor content (42%) and ploidy model (diploid), which corrects for copy-number changes and their effect on variant calling. De novo assembly and annotation of genomic and transcriptomic data using ABySS (v1.3.4) ([@THIBODEAUMCS001628C51]), Trans-ABySS (v1.4.10) ([@THIBODEAUMCS001628C9]; [@THIBODEAUMCS001628C54]), and DELLY v0.6.1 ([@THIBODEAUMCS001628C50]) was utilized to identify structural variants and fusion genes.

The somatic variants were then used to examine mutational signatures/patterns ([@THIBODEAUMCS001628C1]).

RNA expression was analyzed with respect to publically available RNA-seq tumor data sets: The Cancer Genome Atlas (TCGA) Research Network (<http://cancergenome.nih.gov/>) and Illumina Human Body Map 2.0 RNAseq (16 different human tissues). The Illumina Human Body Map 2.0 data can be accessed from ArrayExpress (query \#E-MTAB-513). Gene-based RPKM (transcript-normalized) values were calculated using Ensembl (v69) gene models. To compare to TCGA data sets, a mapping from a given Ensembl gene to the appropriate TGCA gene was determined based on position overlap using the TCGA Generic Annotation File (GAF) files. Several metrics were calculated: percentile, fold change (over the mean), and kIQR. The kIQR is defined as the number of interquartile range intervals away from the median. Given the diagnosis, the TCGA SARC data set (tumor and matched normal) was chosen as the primary comparators and the compendium average of the tissues in the Illumina Human Body Map RNA-seq data set was used as an additional normal tissue comparator. Results were also compared to the full compendium of TCGA cancers data set. For additional details on the sequencing data analytical pipeline used, please refer to [Supplemental Methods](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001628/-/DC1).

Calculation of Mutation Signature Exposures {#s4c}
-------------------------------------------

Somatic SNVs derived from whole-genome sequencing were classified into 96 mutation types representing the base substitution and trinucleotide 5′/3′ context using SomaticSignatures ([@THIBODEAUMCS001628C18]). The mutation signature model, as previously described ([@THIBODEAUMCS001628C1]), takes the form $$\mathbf{m} = {\mathbf{P}\mathbf{e}},$$ where **m** is a 96-element vector enumerating the mutations per class, **P** is a 96-by-30 matrix denoting the relative mutation class frequencies in 30 previously described signatures (available at <http://cancer.sanger.ac.uk/cosmic/signatures>), and **e** is the 30-element exposure that represents the number of mutations contributed by each of the 30 associated mutational processes. As per [@THIBODEAUMCS001628C2], **e** was computed using nonnegative least squares ([@THIBODEAUMCS001628C2]). Monte Carlo resampling was performed to determine the 95% confidence interval of each signature\'s contribution to the overall mutational burden ([Supplemental Methods](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001628/-/DC1); [Supplemental Table S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001628/-/DC1); [Supplemental Figures S3, S4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001628/-/DC1)).

However, because of the lack of previous study of mutation signatures in LMS, we did not limit the signature space to a subset of possible solutions. The exposure of signature 3 was taken to be the homologous recombination deficiency signature.

Determination of Homologous Recombination Deficiency Score {#s4d}
----------------------------------------------------------

The HRD score was determined based on guidelines in previous studies ([@THIBODEAUMCS001628C60]; [@THIBODEAUMCS001628C58]), adapted to whole-genome sequencing data. The HRD score was calculated as an arithmetic sum of HRD-LOH, HRD-TAI, and HRD-LST scores. HRD-LOH was defined as the number of regions of LOH \> 15 Mb in length, but smaller than the whole chromosome. HRD-TAI was defined as the number of regions of allelic imbalance extending to one subtelomere but not across the centromere. Here, a subtelomere was defined as the region between the telomeric boundary and the closest gene, minus a 10-kb flanking region. HRD-LST was defined as the number of breakpoints between regions of \>10 Mb after filtering out regions of \<3 Mb.

Comparison of HRD Scores and Signatures {#s4e}
---------------------------------------

The HRD score and HRD mutation signature were compared against those calculated for 87 breast cancers, 16 ovarian cancers, and 36 sarcomas, sequenced at our Genome Sciences Centre.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

Whole-genome sequencing and RNA-seq data (.bam files) have been submitted to the European Genome-Phenome Archive (EGA) ([www.ebi.ac.uk/ega/home](www.ebi.ac.uk/ega/home)) under data accession number EGAD00001002891. The *CHEK2*:c.1100delC variant has been submitted to ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) under accession number SCV000574565.
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The patient specimens were collected as part of a research project approved by the University of British Columbia Cancer Agency (BCCA) Research Ethics Board (REB) (protocol H14-00681) and are in accordance with the Declaration of Helsinki. Informed written consent was obtained from the patient for tumor profiling using RNA-seq (tumor) as well as whole-genome sequencing (tumor and blood). The use of data sets is allowed for research reports and scientific publications. The protocol allows for data to be not only used for research reports and scientific publication but also to be made available to named investigators of institutions who agree by a data transfer agreement stating they will honor the same ethical and privacy principles required by the BCCA REB.
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